title: Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic cells and macrophages: adjuvant effects and antigen delivery.
abstract: Exposure to proteoliposomes from serogroup B Neisseria meningitidis (PL) induced up-regulation of MHC-II, MHC-I, CD40, CD80 and CD86 expression on the surface of murine bone marrow-derived dendritic cells (DC). CD40, CD80 and CD86 were up-regulated on bone marrow-derived macrophages (MPhi) upon stimulation with PL. Both DC and MPhi released TNFalpha, but only DC produced IL12(p70) in response to PL. A small increase in the expression of MHC-II, CD40 and CD86, as well as production of IL12(p70), was observed on the cell surface of DC, but not MPhi from LPS-non-responder C3H/HeJ after exposure to PL. DC, but not MPhi, incubated with PL containing ovalbumin (PL-OVA) presented OVA-specific peptides to CD4+ and CD8+ OVA-specific T-cell hybridomas. These data clearly indicate that PL exert an immunomodulatory effect on DC and MPhi, with some contribution of non-LPS components besides the main role of LPS. The work also shows the potential of PL as a general system to deliver antigens to DC for presentation to CD4+ and CD8+ T-cells.
authors.affiliation: Department of Immunology, Finlay Institute, PO Box 16017, Havana, Cuba.
authors.forename: Tamara
authors.initials: T
authors.lastname: Rodríguez
authors.forename: Oliver
authors.initials: O
authors.lastname: Pérez
authors.forename: Nathalie
authors.initials: N
authors.lastname: Ménager
authors.forename: Sanja
authors.initials: S
authors.lastname: Ugrinovic
authors.forename: Gustavo
authors.initials: G
authors.lastname: Bracho
authors.forename: Pietro
authors.initials: P
authors.lastname: Mastroeni
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D017951:Antigen Presentation / Q000187:drug effects; D000938:Antigen-Presenting Cells / Q000187:drug effects; D000942:Antigens, Bacterial / Q000008:administration & dosage* / Q000276:immunology*; D001854:Bone Marrow Cells / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002460:Cell Line; D016207:Cytokines / Q000096:biosynthesis; D003713:Dendritic Cells / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D005802:Genes, MHC Class II / Q000502:physiology; D006822:Hybrid Cells; D008264:Macrophages / Q000276:immunology*; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D010047:Ovalbumin / Q000276:immunology; D011510:Proteolipids; D011956:Receptors, Cell Surface / Q000378:metabolism; D051197:Toll-Like Receptor 4; D015854:Up-Regulation
chemical_list: D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D016207:Cytokines; D022401:Meningococcal Vaccines; D011510:Proteolipids; D011956:Receptors, Cell Surface; C493487:Tlr4 protein, mouse; D051197:Toll-Like Receptor 4; C020485:proteoliposomes; D010047:Ovalbumin